{"schema_version":"secwatch.filing_event.v1","accession":"0001656423-23-000020","form_type":"8-K","ticker":"BXP","cik":"0001037540","company_name":"BXP, Inc.","filed_at":"2023-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.708867+00:00","generated_at":"2026-06-16T15:17:57.115749+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BXP Q1 2023 FFO $1.73/share, revenue up 6.5%; commences two life sciences projects in Cambridge","bullets":["Q1 revenue $803.2M (+6.5% YoY); net income $77.9M ($0.50 EPS) vs $143.0M ($0.91 EPS) in Q1 2022.","FFO $272.0M ($1.73/share) vs $286.1M ($1.82/share) in Q1 2022; FFO beat guidance mid-point by $0.06.","Commenced development of 290 Binney St (566k sq ft lab, 100% pre-leased to AstraZeneca for 15 years) and redevelopment of 300 Binney St (236k sq ft lab, pre-leased to Broad Institute for 15 years).","Closed $1.2B term loan facility in Jan 2023; used $730M to repay maturing term loan, net proceeds ~$464M.","Guidance: Q2 2023 EPS $0.59-$0.61, FFO $1.79-$1.81; FY 2023 EPS $2.30-$2.36, FFO $7.14-$7.20."],"urls":{"canonical":"https://secwatch.observer/filing/0001656423-23-000020","json":"https://secwatch.observer/filing/0001656423-23-000020.json","markdown":"https://secwatch.observer/filing/0001656423-23-000020.md","text":"https://secwatch.observer/filing/0001656423-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1037540/000165642323000020/0001656423-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1037540/000165642323000020/bxp-20230425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T15:17:57.115749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"634f8e70f0098a0e9436a8cde10a3eebae2d093f","claim":"BXP, Inc. reported first quarter ended March 31, 2023 results: revenue $803.2 million, net income $77.9 million, EPS $0.50 per diluted share (EPS).","evidence_excerpt":"Financial highlights for the first quarter include: • Revenue increased 6.5% to $803.2 million for the quarter ended March 31, 2023, as compared to $754.3 million for the quarter ended March 31, 2022. • Net income attributable to common shareholders of $77.9 million, or $0.50 per diluted share (EPS), for the quarter ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1037540/000165642323000020/0001656423-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$803.2 million"},{"label":"Net income","value":"$77.9 million"},{"label":"EPS","value":"$0.50 per diluted share (EPS)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}